Trial Profile

An open label, randomized, 2 x 3 crossover study to evaluate bioequivalence between fixed-dose combination of SAH100 tablets (300/5/25mg aliskiren/amlodipine/HCTZ) and free combination of market formulation of 300mg aliskiren tablet, and clinical service formulations of 5mg amlodipine and 25mg hydrochlorothiazide in healthy subjects under light meal conditions

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aliskiren/amlodipine/hydrochlorothiazide (Primary) ; Aliskiren; Amlodipine; Hydrochlorothiazide
Indications Hypertension
Focus Pharmacokinetics
Sponsors Novartis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com